Affiliation:
1. Department of Pharmacokinetics and Drug Metabolism, Product Development Laboratories, Fujisawa Pharmaceutical Co. Ltd, 1–6 2-chome Kashima, Yodogawa-ku, Osaka 532, Japan
Abstract
Abstract
The distribution of FK506 in the blood was estimated in-vitro. At a drug level of 5 ng mL−1, FK506 mainly distributed in erythrocytes (95–98%) in dog, monkey and human blood, and its distribution was affected by drug concentration, temperature, and haematocrit values. In erythrocytes most of FK506 was distributed in cytoplasmic components and was bound strongly to a protein having a molecular weight of 10–11 kDa. The molecular weight of this protein agrees with FK506-binding protein found in various cells. Greater than 98·8% of FK506 was bound to the plasma proteins in all species studied. FK506 bound to various plasma proteins such as lipoproteins, globulins, α1-acid glycoprotein and albumin.
Publisher
Oxford University Press (OUP)
Subject
Pharmaceutical Science,Pharmacology
Reference16 articles.
1. Evidence of a cyclosporine binding protein in human erythrocytes;Agarwal;Transplantation.,1986
2. A randomized trial of primary liver transplantation under immunosuppression with FK506 vs cyclosporin;Fung;Transplant. Proc.,1991
3. Identification of cyclophilin as the erythrocyte cyclosporin-binding protein;Foxwell;Biochim. Biophys. Acta.,1988
4. FK506: historical perspectives;Goto;Transplant. Proc.,1991
5. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum;Havel;J. Clin. Invest.,1955
Cited by
100 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献